{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=73",
    "query": {
      "intervention": "Dose Level 3",
      "page": 73
    },
    "page_size": 10
  },
  "pagination": {
    "page": 73,
    "page_size": 10,
    "total_count": 17842,
    "total_pages": 1785,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=74&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=72&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T22:39:27.486Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01180036",
      "title": "MEmbranous Nephropathy Trial Of Rituximab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 130,
      "start_date": "2011-11",
      "completion_date": "2017-10-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01180036"
    },
    {
      "nct_id": "NCT06721871",
      "title": "Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Microvillus Inclusion Disease",
        "Congenital Disorders",
        "Rare Diseases"
      ],
      "interventions": [
        {
          "name": "Crofelemer Powder for Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Powder for Oral Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Napo Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 6,
      "start_date": "2025-05-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06721871"
    },
    {
      "nct_id": "NCT03195699",
      "title": "Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Hepatocellular Cancer",
        "Colorectal Cancer",
        "Gastric Adenocarcinoma",
        "Melanoma",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "TTI-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tvardi Therapeutics, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2017-11-15",
      "completion_date": "2024-06-24",
      "has_results": false,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03195699"
    },
    {
      "nct_id": "NCT01076699",
      "title": "A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "0.075 mg RVX-100",
          "type": "DRUG"
        },
        {
          "name": "0.125 mg RVX-100",
          "type": "DRUG"
        },
        {
          "name": "0.250 mg RVX-100",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revogenex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 192,
      "start_date": "2010-03",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2010-07-19",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 1,
      "location_summary": "Chevy Chase, Maryland",
      "locations": [
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076699"
    },
    {
      "nct_id": "NCT07285798",
      "title": "A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Irritability Associated With Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "KarXT",
          "type": "DRUG"
        },
        {
          "name": "KarX-EC",
          "type": "DRUG"
        },
        {
          "name": "KarXT + KarX-EC Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 176,
      "start_date": "2026-10-06",
      "completion_date": "2029-08-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Glendale, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285798"
    },
    {
      "nct_id": "NCT04046549",
      "title": "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allografts",
        "Rejection; Transplant, Kidney",
        "Transplant Rejection",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "VIB4920",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-10-30",
      "completion_date": "2023-03-22",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04046549"
    },
    {
      "nct_id": "NCT00783549",
      "title": "A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dyslipidaemias"
      ],
      "interventions": [
        {
          "name": "an undetermined dose of GSK1292263",
          "type": "DRUG"
        },
        {
          "name": "ascending dose of GSK1292263",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 76,
      "start_date": "2008-09-04",
      "completion_date": "2009-03-31",
      "has_results": false,
      "last_update_posted_date": "2017-07-07",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00783549"
    },
    {
      "nct_id": "NCT02469701",
      "title": "Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Lung Cancer",
        "Metastatic Lung Cancer",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "nivolumab and ablation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "howard safran",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-02",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02469701"
    },
    {
      "nct_id": "NCT02489500",
      "title": "Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AL Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Neupogen",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2015-06",
      "completion_date": "2017-04-28",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02489500"
    },
    {
      "nct_id": "NCT01081964",
      "title": "Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community Acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Zabofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin 500mg",
          "type": "DRUG"
        },
        {
          "name": "Zabofloxacin 400mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IASO Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2010-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-05-07",
      "last_synced_at": "2026-11-18T22:39:27.486Z",
      "location_count": 13,
      "location_summary": "Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Toney",
          "state": "Alabama"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Eagle",
          "state": "Idaho"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081964"
    }
  ]
}